Bryan, Garnier & Co successfully advised Pierrel on its EUR 17.1 million follow-on offering
Share the transaction
Paris- August 28th, 2008 – Bryan, Garnier & Co (“Bryan Garnier”), the independent pan-European investment bank focused on European growth companies, today announced it has advised Pierrel S.p.A on its EUR 17.1 million follow-on offering.
Bryan, Garnier & Co acted as Co-manager on this transaction.
For more information, please contact:
Giuseppe Albanese – Director Corporate Broking / +33 1 56 68 75 34 / galbanese@bryangarnier.com
About Pierrel
Pierrel S.p.A., provider in the pharmaceutical trade, specializing in Contract Research, development and the manufacture of medicines, is listed on the Expandi market run by Borsa Italiana. The Pierrel Group can boast experience of over 50 years in the pharmaceutical sector, and is one of the main manufacturers in Italy of local anesthetics for dental use. The Pierrel Group mainly operates in the field of outsourcing for pharmaceutical companies, and is particularly active in two areas: the production of specially commissioned medicines (Contract Manufacturing) and a consultancy service for research and development of new molecules and drugs (Contract Research).
Pierrel S.p.A., based in Milan with its production plant in Capua (Caserta), is a reference-point partner for some of the most important pharmaceutical firms in the given sectors. Pierrel controls the Swiss company Pharmapart AG and the German Company IFE Europe GmbH, and the Hungarian company Goodwill Research, and Hypepharm